New drug tarlatamab targets Hard-to-Treat brain tumors

NCT ID NCT06776250

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests tarlatamab, a drug that helps immune cells attack tumor cells, in 44 adults with recurrent IDH-mutant gliomas (a type of brain tumor). The study aims to see if tarlatamab can increase immune cell activity in the tumor and potentially control the disease. Participants must have had up to two prior treatments and be eligible for surgery or biopsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tarlatamab
What this could lead to: If successful, this could point toward a new treatment option for people with recurrent IDH-mutant gliomas, potentially helping to control tumor growth.
What could go wrong: This is an early phase 2 trial with only 44 participants, so results may not apply to everyone. The drug's effectiveness and safety in the brain are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTIC TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytic tumor astrocytoma (excluding glioblastoma) oligodendroglial tumor oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTROCYTIC TUMOR OLIGODENDROGLIAL TUMOR

Contacts and locations

Locations

Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.